Senescence of Alveolar Type 2 Cells Drives Progressive Pulmonary Fibrosis
Changfu Yao(Cedars-Sinai Medical Center), Barry R. Stripp(Cedars-Sinai Medical Center), Tanyalak Parimon(Institute for Women's Policy Research), John A. Belperio(University of California, Los Angeles), Harmik J. Soukiasian(Cedars-Sinai Medical Center), Guanling Huang(Computational Diagnostics (United States)), Xiangrong Guan(Institute for Women's Policy Research), Paul W. Noble(Cedars-Sinai Medical Center), Dianhua Jiang(Cedars-Sinai Medical Center), Gianni Carraro(Lung Institute), Xue Liu(Nankai University), Gregory David(New York University), Apoorva Mulay(Cedars-Sinai Medical Center), Peter Chen(Cedars-Sinai Medical Center), S. Weigt(University of California, Los Angeles)
American Journal of Respiratory and Critical Care Medicine
September 29, 2020
Cited by 548
Related Papers
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
|The Lancet|2011|2.1k
Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition
|Proceedings of the National Academy of Sciences|2011|1.1k
Repair and Regeneration of the Respiratory System: Complexity, Plasticity, and Mechanisms of Lung Stem Cell Function
|Cell stem cell|2014|929
Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44.
|Journal of Clinical Investigation|1996|806